
T2 Biosystems TTOO
Quarterly report 2024-Q3
added 11-14-2024
T2 Biosystems General and Administrative Expenses 2011-2026 | TTOO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.8 M | 30.6 M | 28.5 M | 21.3 M | 27.3 M | 25.7 M | 22.8 M | 24.1 M | 19.1 M | 11 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.6 M | 11 M | 23.5 M |
Quarterly General and Administrative Expenses T2 Biosystems
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.38 M | 5.47 M | 6.74 M | - | 5.98 M | 6.3 M | 7.3 M | - | 7.02 M | 7.82 M | 9.23 M | - | 8.54 M | 7.24 M | 6.2 M | - | 5.27 M | 5.3 M | 6.66 M | 7.55 M | 5.98 M | 6.72 M | 7.06 M | 6.46 M | 5.87 M | 7.61 M | 5.76 M | 5.56 M | 5.56 M | 5.76 M | 5.87 M | 5.8 M | 5.94 M | 6.14 M | 6.2 M | 5.01 M | 5.18 M | 4.44 M | 4.47 M | 3.75 M | 2.98 M | 2.45 M | 1.84 M | - | 1.28 M | 1.3 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.23 M | 1.28 M | 5.68 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 1.63 | -1.21 % | $ 2.17 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 114.87 | -0.65 % | $ 34.9 B | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 24.7 | -1.12 % | $ 686 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
CareDx, Inc
CDNA
|
108 M | $ 21.91 | 0.27 % | $ 1.17 B | ||
|
Illumina
ILMN
|
1.09 B | $ 126.92 | -1.24 % | $ 20.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 15.3 | -1.92 % | $ 463 M | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 83.55 | -0.67 % | $ 5.64 B | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 166.79 | -2.59 % | $ 8.27 B | ||
|
National Research Corporation
NRC
|
54.8 M | $ 16.84 | -1.58 % | $ 377 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Guardant Health
GH
|
211 M | $ 83.09 | -6.11 % | $ 10.4 B | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 27.12 | -1.53 % | $ 20 B | ||
|
Precipio
PRPO
|
9.45 M | $ 31.75 | 3.42 % | $ 51 M | ||
|
Personalis
PSNL
|
46.2 M | $ 5.5 | -7.72 % | $ 326 M | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 1.93 | - | $ 8.54 M | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 7.18 | -1.24 % | $ 300 M | ||
|
Medpace Holdings
MEDP
|
198 M | $ 409.65 | -2.78 % | $ 11.8 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.19 | 0.46 % | $ 5.03 M | ||
|
Thermo Fisher Scientific
TMO
|
8.73 B | $ 470.22 | 0.47 % | $ 177 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 102.49 | -0.7 % | $ 8.45 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 259.57 | -1.47 % | $ 21.6 B | ||
|
Trinity Biotech plc
TRIB
|
24.7 M | $ 0.61 | -4.93 % | $ 61.9 M | ||
|
Neogen Corporation
NEOG
|
218 M | $ 9.34 | -1.16 % | $ 2.03 B | ||
|
Celcuity
CELC
|
27.2 M | $ 120.07 | -4.46 % | $ 5.61 B | ||
|
Twist Bioscience Corporation
TWST
|
247 M | $ 59.15 | -3.03 % | $ 3.54 B | ||
|
NeoGenomics
NEO
|
273 M | $ 9.02 | 4.76 % | $ 1.16 B | ||
|
Myriad Genetics
MYGN
|
257 M | $ 4.84 | 0.21 % | $ 448 M | ||
|
Natera
NTRA
|
589 M | $ 200.17 | -2.06 % | $ 19.7 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 195.05 | -0.8 % | $ 21.7 B | ||
|
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | ||
|
OpGen
OPGN
|
4.54 M | - | -16.95 % | $ 1.54 M |